Germany's Merck KGaA has for some years been taking steps to cash in on the growing population in emerging markets of people needing treatment for diabetes and associated conditions, sometimes building plants to make its diabetes treatments locally. Working through a joint venture, a plant is starting production in North Africa.
In yet another recall of acetaminophen, Midway Importing is recalling nearly 165,000 boxes of Sedalmex. But Midway is not the producer. That is Merck KGaA, which manufactured the pain reliever at a plant in Mexico.
Merck KGaA has been playing a guessing game. The rules: Look at 6 photographs, each from a pharma company website, and try to figure out which belongs to Merck KGaA. It's a challenge that's been foiling players from both inside and outside the company, the pharma's head of branding and communications strategy, Axel Löber, told FiercePharmaMarketing.
Merck KGaA has a new leadership team in healthcare, and as of Tuesday, a newly named successor to its CEO. Now it's working on a new brand identity.
Pharma bigwigs Merck KGaA and Pfizer announced they are collaborating with Dako to develop a companion diagnostic to accompany their investigational immune checkpoint inhibiting candidate in the fight against cancer.
Genea Biomedx partnered its three fertility products in development with Merck KGaA last month. Now it's won a CE mark for two of them: the Gavi automated vitrification instrument and the Geri benchtop incubator.
Sales for Merck KGaA's OTC unit posted a double-digit jump in Q1, and it was no accident. The company has been doubling down on the "consumer" part of "consumer health"--a move it says is paying off.
Effective branding is important for any company. But it becomes even more important when you share a name with another company--especially when that other company is your rival.
When Pfizer teamed up with Merck KGaA on lung cancer, the headlines zeroed in on the sexiest part of the $2.85 billion deal: their immuno-oncology plans. The two companies will work together on cancer-fighters in the PD-L1 arena, one of the hottest fields in pharma these days, including a Phase II Merck drug.
Germany's Merck KGaA now considers the world's emerging markets as a group, with China a major driver, to be a greater revenue-producer than Europe, unit CEO Bernd Reckmann said in an interview.